229 related articles for article (PubMed ID: 1825196)
21. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W
Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
[No Abstract] [Full Text] [Related]
22. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.
De Jong R; Brouwer M; Rebel VI; Van Seventer GA; Miedema F; Van Lier RA
Immunology; 1990 Jul; 70(3):357-64. PubMed ID: 2143171
[TBL] [Abstract][Full Text] [Related]
23. Effect of the HLA-DRw6 antigen in liver transplantation.
Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
[No Abstract] [Full Text] [Related]
24. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
Norman DJ
Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
[TBL] [Abstract][Full Text] [Related]
25. [Perspectives of immunosuppressive therapy].
Meuer S; Sido B; Dengler T
Chirurg; 1996 Apr; 67(4):310-7. PubMed ID: 8646915
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
[No Abstract] [Full Text] [Related]
27. The clinical application of monoclonal antibody therapies in renal transplantation.
Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
[TBL] [Abstract][Full Text] [Related]
28. In vivo-in vitro correlates of human rejection using flow cytometry with two-color fluorescence on peripheral blood mononuclear cells.
Gross U; Thomas F; Matthews C; Thomas J; Cunningham P; Ritter T
Transplant Proc; 1987 Feb; 19(1 Pt 2):1609-10. PubMed ID: 2978885
[No Abstract] [Full Text] [Related]
29. Signaling normal human T-cells: synergism between CD2 antigen and CD3/T cell receptor alpha beta complex in the elicitation of IL-2 and IL-2 receptor gene expression.
Li B; Sehajpal P; Estin D; Fotino M; Suthanthiran M
Transplant Proc; 1991 Feb; 23(1 Pt 1):77-8. PubMed ID: 1671306
[No Abstract] [Full Text] [Related]
30. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
[No Abstract] [Full Text] [Related]
31. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation.
Verwilghen J; Baroja ML; Van Vaeck F; Van Damme J; Ceuppens JL
Immunology; 1991 Feb; 72(2):269-76. PubMed ID: 1826671
[TBL] [Abstract][Full Text] [Related]
32. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
J Immunol; 1993 Jun; 150(11):5163-74. PubMed ID: 7684422
[TBL] [Abstract][Full Text] [Related]
33. HLA typing using IL-2 activated T lymphocytes: usefulness in pediatric candidates for allogeneic bone marrow transplantation.
Kubo K; Tachino J; Ichikawa S; Hamamoto K; Ueda K
Bone Marrow Transplant; 1991 Sep; 8(3):185-90. PubMed ID: 1720338
[TBL] [Abstract][Full Text] [Related]
34. The use of an anti-CD3 priming dose to enhance the immunosuppressive potency of monoclonal and polyclonal T-cell antisera.
Sherburne CG; Onyekaba CO; Condie RM
Transplant Proc; 1991 Feb; 23(1 Pt 1):626-9. PubMed ID: 1824996
[No Abstract] [Full Text] [Related]
35. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
[No Abstract] [Full Text] [Related]
36. Adverse responses following intraoperative administration of orthoclone OKT3.
Roth S; Kupferberg JP
Anesth Analg; 1989 Dec; 69(6):822-5. PubMed ID: 2531559
[No Abstract] [Full Text] [Related]
37. Transplantation immunology.
Krensky AM; Clayberger C
Pediatr Clin North Am; 1994 Aug; 41(4):819-39. PubMed ID: 8047371
[TBL] [Abstract][Full Text] [Related]
38. Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3.
Ellenhorn JD; Hirsch R; Hartley JP; Bluestone JA
Transplant Proc; 1989 Feb; 21(1 Pt 1):1013-4. PubMed ID: 2523110
[No Abstract] [Full Text] [Related]
39. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
[No Abstract] [Full Text] [Related]
40. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
Shield CF; Hughes JD; Marlett P; Norman DJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
